Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome

C. L. Koski, E. G. Gratz, J. Sutherland, R. F. Mayer

Research output: Contribution to journalArticle

Abstract

Anti-peripheral-nerve myelin antibodies (anti-PNM Ab) can be detected in the serum of all patients with acute-phase Guillain-Barre syndrome (GBS) thus far tested. Correlation of the titer of this antibody with the clinical course would help to establish a role for the humoral immune system in the pathophysiology of GBS. In this study, anti-PNM Ab levels were measured in serial serum samples of 7 patients with GBS with an assay that detects antibodies bound to peripheral nerve myelin antigens by fixation of the first component of complement. Although the titers of anti-PNM Ab detected in these patients varied between 0 and 256 U/ml, the antibody titer was always highest on admission (35 to 256 U/ml) and rapidly declined during a one-to-three-week period. Disappearance of antibodies or very low levels of them correlated with cessation of progression and considerable clinical improvement as documented by increased pulmonary vital capacity and muscular strength. Low but measurable antibody titers (5 to 12 U/ml) were frequently found up to four months following the acute neurological deficit. The close temporal relationship between anti-PNM Ab titer and the clinical course in GBS suggests that antibody most likely participates through complement activation in peripheral nerve demyelination.

Original languageEnglish (US)
Pages (from-to)573-577
Number of pages5
JournalAnnals of Neurology
Volume19
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Guillain-Barre Syndrome
Myelin Sheath
Peripheral Nerves
Antibodies
Lung Volume Measurements
Complement Activation
Vital Capacity
Demyelinating Diseases
Serum
Immune System
Antigens

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome. / Koski, C. L.; Gratz, E. G.; Sutherland, J.; Mayer, R. F.

In: Annals of Neurology, Vol. 19, No. 6, 1986, p. 573-577.

Research output: Contribution to journalArticle

Koski, C. L. ; Gratz, E. G. ; Sutherland, J. ; Mayer, R. F. / Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome. In: Annals of Neurology. 1986 ; Vol. 19, No. 6. pp. 573-577.
@article{ae3013bcf9884ee69c444591bfe73878,
title = "Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome",
abstract = "Anti-peripheral-nerve myelin antibodies (anti-PNM Ab) can be detected in the serum of all patients with acute-phase Guillain-Barre syndrome (GBS) thus far tested. Correlation of the titer of this antibody with the clinical course would help to establish a role for the humoral immune system in the pathophysiology of GBS. In this study, anti-PNM Ab levels were measured in serial serum samples of 7 patients with GBS with an assay that detects antibodies bound to peripheral nerve myelin antigens by fixation of the first component of complement. Although the titers of anti-PNM Ab detected in these patients varied between 0 and 256 U/ml, the antibody titer was always highest on admission (35 to 256 U/ml) and rapidly declined during a one-to-three-week period. Disappearance of antibodies or very low levels of them correlated with cessation of progression and considerable clinical improvement as documented by increased pulmonary vital capacity and muscular strength. Low but measurable antibody titers (5 to 12 U/ml) were frequently found up to four months following the acute neurological deficit. The close temporal relationship between anti-PNM Ab titer and the clinical course in GBS suggests that antibody most likely participates through complement activation in peripheral nerve demyelination.",
author = "Koski, {C. L.} and Gratz, {E. G.} and J. Sutherland and Mayer, {R. F.}",
year = "1986",
language = "English (US)",
volume = "19",
pages = "573--577",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barre syndrome

AU - Koski, C. L.

AU - Gratz, E. G.

AU - Sutherland, J.

AU - Mayer, R. F.

PY - 1986

Y1 - 1986

N2 - Anti-peripheral-nerve myelin antibodies (anti-PNM Ab) can be detected in the serum of all patients with acute-phase Guillain-Barre syndrome (GBS) thus far tested. Correlation of the titer of this antibody with the clinical course would help to establish a role for the humoral immune system in the pathophysiology of GBS. In this study, anti-PNM Ab levels were measured in serial serum samples of 7 patients with GBS with an assay that detects antibodies bound to peripheral nerve myelin antigens by fixation of the first component of complement. Although the titers of anti-PNM Ab detected in these patients varied between 0 and 256 U/ml, the antibody titer was always highest on admission (35 to 256 U/ml) and rapidly declined during a one-to-three-week period. Disappearance of antibodies or very low levels of them correlated with cessation of progression and considerable clinical improvement as documented by increased pulmonary vital capacity and muscular strength. Low but measurable antibody titers (5 to 12 U/ml) were frequently found up to four months following the acute neurological deficit. The close temporal relationship between anti-PNM Ab titer and the clinical course in GBS suggests that antibody most likely participates through complement activation in peripheral nerve demyelination.

AB - Anti-peripheral-nerve myelin antibodies (anti-PNM Ab) can be detected in the serum of all patients with acute-phase Guillain-Barre syndrome (GBS) thus far tested. Correlation of the titer of this antibody with the clinical course would help to establish a role for the humoral immune system in the pathophysiology of GBS. In this study, anti-PNM Ab levels were measured in serial serum samples of 7 patients with GBS with an assay that detects antibodies bound to peripheral nerve myelin antigens by fixation of the first component of complement. Although the titers of anti-PNM Ab detected in these patients varied between 0 and 256 U/ml, the antibody titer was always highest on admission (35 to 256 U/ml) and rapidly declined during a one-to-three-week period. Disappearance of antibodies or very low levels of them correlated with cessation of progression and considerable clinical improvement as documented by increased pulmonary vital capacity and muscular strength. Low but measurable antibody titers (5 to 12 U/ml) were frequently found up to four months following the acute neurological deficit. The close temporal relationship between anti-PNM Ab titer and the clinical course in GBS suggests that antibody most likely participates through complement activation in peripheral nerve demyelination.

UR - http://www.scopus.com/inward/record.url?scp=0022461301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022461301&partnerID=8YFLogxK

M3 - Article

C2 - 3729311

AN - SCOPUS:0022461301

VL - 19

SP - 573

EP - 577

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -